Figure S5 from Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity

Autor: Marc S. Ernstoff, Elizabeth A. Repasky, Hemn Mohammadpour, Igor Puzanov, Mark J. Bucsek, Joseph J. Drabick, Pauline Funchain, Suzanne Stack, Maria Levis, Carlos D. Cedeno, Paul K. Wallace, Joseph D. Tario, Cheryl Allen, Erik S. Knudsen, Agnieszka K. Witkiewicz, Wenyan Ji, Kristopher Attwood, Manu R. Pandey, Shipra Gandhi
Rok vydání: 2023
DOI: 10.1158/1078-0432.22479668.v1
Popis: 10x magnification of hematoxylin and eosin stained slides of archival tissue biopsies of patients at dose level 1, 2 and 3 on the study. Dose level 1 is propranolol 10 mg BID, dose level 2 is propranolol 20 mg BID, dose level 3 is propranolol 30 mg BID
Databáze: OpenAIRE